Intracranial meningioma: Experience with stereotactic radiotherapy.
Autor: | Ragos V; Department of Maxillofacial Surgery, Medical School, University of Ioannina, Greece., Yazici O, Guzle Adas Y, Kekilli E, Calikoglu T, Bedri Altundag M, Riza Ucer A, Ertas G, Durmus Duzgun S, Ozbagi K, Demirkasimoglu A, Demir E, Aslan B, Kaya B |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of B.U.ON. : official journal of the Balkan Union of Oncology [J BUON] 2018 Jul-Aug; Vol. 23 (4), pp. 1169-1173. |
Abstrakt: | Purpose: Definitive radiotherapy is a treatment option for patients with inoperable meningiomas. The purpose of this study was to evaluate the results of stereotactic radiotherapy as first-line treatment for intracranial meningiomas that were diagnosed radiologically. Methods: Between January 2010 and June 2016, 56 patients with intracranial meningioma treated with Cyberknife- based Stereotactic Radiosurgery (SRS) or hypofractionated stereotactic radiotherapy (hFSRT) were included. The median prescribed radiation dose was 16 Gy (range 13-18) for SRS and 25 Gy (range 18-33) for hFSRT. hFSRT doses were delivered in 3 to 5 fractions. Results: Median follow-up was 58 months (range 6-97). Overall survival (OS) for the whole group was 89.2%; for SRS group it was 100% and for hFSRT group 87.5% (p=0.29). Progression free survival (PFS) for the whole group was 89.3%; for SRS group it was 87.5% and for hFSRT 89.5% at 5 years (p=0.93). Conclusion: SRS and hFSRT were effective with excellent local control rates and they can be an alternative treatment option for patients with inoperable meningiomas. |
Databáze: | MEDLINE |
Externí odkaz: |